Dr Dan Gooding, CEO of Nuformix and author of The Crypto Trader, Glen Goodman
Justin Waite
Vox Markets Podcast with Justin Waite
11:47, 6th September 2019

Vox Media Player

DYOR Disclaimer

If you find this podcast useful please give it a rating and review on iTunes by clicking here

Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here: www.VoxMarkets.co.uk/app


On today's Vox Markets Podcast: Dr Dan Gooding, CEO of Nuformix and author of The Crypto Trader, Glen Goodman

Dr Dan Gooding, CEO of Nuformix (NFX) FOLLOW talks about the appointment of Dr Muhunthan Thillai to their Scientific Advisory Board and also coves progress in other areas of the business.

Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix's risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules. Nuformix has created an IP portfolio of granted patents covering cocrystal forms of five small molecule drugs. Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.


Glen Goodman, former ITV News Business correspondent and now author of, "The Crypto Trader", provides some insights into the world of crypto currency trading.

(Interview starts at 9 minutes 17 seconds)

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Comments
info
Login or register to post comments

Recent Articles
Watchlist